Conditions: Refractory Leukemia Acute Myelogenous Leukemia
Keywords: Acute myeloid leukemia AML relapsed acute myeloid leukemia refractory AML refractory de novo AML refractory secondary AML secondary AML AML following myelodysplastic syndrome (MDS) AML following antecedent hematological disorder (AHD) AML resistant to therapy
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.

Detailed description:

Arms:
arm 1: patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week. arm 2: patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.

Interventions: intervention 1: Panobinostat/LBH589
Intervention descriptions: intervention 1: None

Protocol document: